Valneva SE

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0004056851
EUR
2.76
-0.04 (-1.57%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Risky -

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -17.65%, its profits have fallen by -1276.8%
2

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 488 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.03

stock-summary
Return on Equity

-108.50%

stock-summary
Price to Book

4.60

Revenue and Profits:
Net Sales:
48 Million
(Quarterly Results - Dec 2025)
Net Profit:
-50 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-23.45%
0%
-23.45%
6 Months
-34.61%
0%
-34.61%
1 Year
-17.65%
0%
-17.65%
2 Years
-23.09%
0%
-23.09%
3 Years
-42.07%
0%
-42.07%
4 Years
-82.37%
0%
-82.37%
5 Years
-73.13%
0%
-73.13%

Valneva SE for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
11.66%
EBIT Growth (5y)
-9.96%
EBIT to Interest (avg)
-5.36
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
13.38
Tax Ratio
2.85%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.16
EV to EBIT
-9.06
EV to EBITDA
-11.08
EV to Capital Employed
4.53
EV to Sales
4.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-49.98%
ROE (Latest)
-67.89%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 62.24% vs -39.13% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -12.61% vs -282.76% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "47.70",
          "val2": "29.40",
          "chgp": "62.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-24.90",
          "val2": "-35.20",
          "chgp": "29.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "24.60",
          "val2": "5.70",
          "chgp": "331.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-50.00",
          "val2": "-44.40",
          "chgp": "-12.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-639.50%",
          "val2": "-1,379.90%",
          "chgp": "74.04%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 3.01% vs 10.34% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -844.26% vs 87.97% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "174.70",
          "val2": "169.60",
          "chgp": "3.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-70.20",
          "val2": "-79.00",
          "chgp": "11.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "41.90",
          "val2": "24.00",
          "chgp": "74.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "6.00",
          "val2": "10.90",
          "chgp": "-44.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-115.20",
          "val2": "-12.20",
          "chgp": "-844.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-531.50%",
          "val2": "-581.20%",
          "chgp": "4.97%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
47.70
29.40
62.24%
Operating Profit (PBDIT) excl Other Income
-24.90
-35.20
29.26%
Interest
24.60
5.70
331.58%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-50.00
-44.40
-12.61%
Operating Profit Margin (Excl OI)
-639.50%
-1,379.90%
74.04%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 62.24% vs -39.13% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -12.61% vs -282.76% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
174.70
169.60
3.01%
Operating Profit (PBDIT) excl Other Income
-70.20
-79.00
11.14%
Interest
41.90
24.00
74.58%
Exceptional Items
6.00
10.90
-44.95%
Consolidate Net Profit
-115.20
-12.20
-844.26%
Operating Profit Margin (Excl OI)
-531.50%
-581.20%
4.97%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 3.01% vs 10.34% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -844.26% vs 87.97% in Dec 2024

stock-summaryCompany CV
About Valneva SE stock-summary
stock-summary
Valneva SE
Pharmaceuticals & Biotechnology
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has also vaccines in development, including candidates against Clostridium difficile and Lyme Borreliosis. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products. It cooperates with various pharmaceutical companies using its technology platforms: EB66 vaccine production cell line and IC31 adjuvant. The Company has operations in France, Austria, Scotland, Canada and Sweden.
Company Coordinates stock-summary
Company Details
Campus Bio-Ouest, 6, Rue Alain Bombard , SAINT-HERBLAIN None : 44800
stock-summary
Tel: 33 2 28073710
stock-summary
Registrar Details